PATENT CLAIM ANALYSIS

Application Number: 16197106
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["424", "454000"]

Abstract:
The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 μg/kg body weight/minute and 20 μg/kg body weight/minute.

Claim (Index 3):
The method according to  claim 1  wherein the subject is a human.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 98.0
- Lexical Diversity: 1.6383
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16029239', '14238961', '15538123', '10586209', '12467214']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.711044865186618
- 35 USC 102 Novelty (BERT): 0.5779632734020206
- Combined Prediction Score: 0.6977367060081583
- Mean Citation Score: 304.942146
- Max Citation Score: 452.5346
- Similarity Product: 417.0091626757384

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test